A
9.38
0.01 (0.11%)
| Previous Close | 9.37 |
| Open | 9.35 |
| Volume | 351,115 |
| Avg. Volume (3M) | 1,959,412 |
| Market Cap | 1,329,783,808 |
| Price / Sales | 2.17 |
| Price / Book | 50.98 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -31.06% |
| Operating Margin (TTM) | -20.35% |
| Diluted EPS (TTM) | -1.26 |
| Quarterly Revenue Growth (YOY) | 27.40% |
| Total Debt/Equity (MRQ) | 2,535.20% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -80.18 M |
| Levered Free Cash Flow (TTM) | -125.79 M |
| Return on Assets (TTM) | -12.10% |
| Return on Equity (TTM) | -21,137.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Alphatec Holdings, Inc. | Bullish | Mixed |
AIStockmoo Score
0.9
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | 0.88 |
|
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 25.55% |
| % Held by Institutions | 63.96% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 113.22%) | Buy |
| 20.00 (Barclays, 113.22%) | Buy | |
| Median | 20.00 (113.22%) | |
| Low | 13.00 (Needham, 38.59%) | Buy |
| Average | 17.67 (88.38%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 19 Nov 2024 | 20.00 (113.22%) | Buy | 9.57 |
| HC Wainwright & Co. | 31 Oct 2024 | 20.00 (113.22%) | Buy | 7.85 |
| Needham | 31 Oct 2024 | 13.00 (38.59%) | Buy | 7.85 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Dec 2024 | Announcement | ATEC to Present at the 2025 J.P. Morgan Healthcare Conference |
| 04 Nov 2024 | Announcement | ATEC to Participate in Upcoming Conferences |
| 30 Oct 2024 | Announcement | ATEC Reports Third Quarter 2024 Financial Results And Raises Full-Year Guidance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |